The Trojan Horse Problem
Using viruses to deliver therapeutic payloads is one of modern medicine's most elegant strategies. Whether the goal is to introduce a corrective gene in gene therapy, express a pathogen's antigen in a vaccine, or selectively destroy cancer cells using an oncolytic virus, the fundamental mechanism remains the same: we co-opt a virus's natural ability to infiltrate human cells.
However, this strategy faces a formidable evolutionary barrier: the host immune system. Because human populations are constantly exposed to wild-type viruses, many individuals possess pre-existing neutralizing antibodies against common viral backbones. When a viral vector is administered, the host's immune memory recognizes the vehicle itself rather than the therapeutic payload inside it. This phenomenon, known as anti-vector immunity, neutralizes the vector in systemic circulation before it can reach its target tissue, severely limiting the efficacy of the treatment.
How Anti-Vector Immunity Sabotages Delivery
To understand why anti-vector immunity is such a persistent hurdle, we must look at how it disrupts different therapeutic modalities.
1. The Vaccine "Ceiling Effect"
In viral-vectored vaccines, such as those utilizing human adenovirus serotype 5 (HAdV-C5), high global seroprevalence means many patients destroy the vaccine vehicle upon injection. As shown by Keda Chen et al. in Adenovirus Vaccine Containing Truncated SARS-CoV-2 Spike Protein S1 Subunit Leads to a Specific Immune Response in Mice, widespread pre-existing immunity can significantly diminish the resulting antigen-specific immune response.
Furthermore, prior exposure creates a "ceiling effect." As Tongling Xiao et al. observed in Immunogenicity and safety of quadrivalent influenza vaccine among young and older adults in Tianjin, China: implication of immunosenescence as a risk factor, individuals with high baseline antibody levels experience a significantly diminished fold-increase in response to subsequent doses. This interference is compounded when the same vector is used for booster shots; the primary dose effectively immunizes the patient against the delivery vehicle itself, causing the immune system to intercept subsequent doses (Pierre‐Alexandre Bart et al. in HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial).
2. Oncolytic Virus Clearance
In cancer therapy, oncolytic viruses are engineered to replicate within and destroy tumor cells. While intravenous delivery is ideal for reaching metastatic sites, systemic circulation exposes the virus directly to circulating neutralizing antibodies.
The authors of Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer noted that host neutralizing antibodies rapidly clear oncolytic viruses before they can colonize tumors. This rapid clearance reduces systemic efficacy and limits the therapeutic window (Rao Fu et al. in Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects). To circumvent this, clinicians are often forced to rely on direct intratumoral injections, which are technically challenging and impractical for deep-seated or widespread metastases (Hui Dong et al. in Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages; Qianyun He et al. in Efficacy and adverse reaction management of oncolytic viral intervention combined with chemotherapy in patients with liver metastasis of gastrointestinal malignancy).
3. The Single-Shot Constraint in Gene Therapy
For chronic genetic diseases requiring long-term expression, viral vectors like Adeno-associated viruses (AAV) or adenoviruses are highly effective for initial delivery. However, natural exposure or the first therapeutic dose primes the immune system against the capsid (Huifang Peng et al. in In vivo applications and toxicities of AAV-based gene therapies in rare diseases). This immune response prevents repeated administration, turning potentially curative chronic therapies into strict "single-shot" opportunities (Luyao Wang et al. in In Vivo Delivery Systems for Therapeutic Genome Editing; Yuquan Xie et al. in In Vivo Delivery of Adenoviral Vector Containing Interleukin-17 Receptor A Reduces Cardiac Remodeling and Improves Myocardial Function in Viral Myocarditis Leading to Dilated Cardiomyopathy).
Strategies to Bypass the Immune Wall
To unlock the full potential of viral therapeutics, researchers have engineered several clever workarounds designed to slip past the immune system's radar.
Heterologous Prime-Boost Regimens
The most straightforward way to avoid anti-vector immunity during multi-dose regimens is to change the vehicle between doses. By using a different viral vector or a purified protein for the booster shot, the immune system cannot neutralize the second dose using antibodies generated by the first.
For example, Yifan Sun et al. demonstrated in Vesicular stomatitis virus-based vaccine targeting plasmodium blood-stage antigens elicits immune response and protects against malaria with protein booster strategy that a vesicular stomatitis virus (VSV) prime followed by a protein boost successfully avoids the anti-vector neutralization that cripples homologous booster strategies. In clinical settings, heterologous regimens—such as priming with an adenovirus vector and boosting with a poxvirus—have consistently outperformed homologous sequences (Pierre‐Alexandre Bart et al. in HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial).
Furthermore, trials evaluating heterologous Ad26.ZEBOV and MVA-BN-Filo protocols show that optimizing the interval between these distinct vectors can yield highly robust immune responses even in populations with baseline adenovirus exposure (Houreratou Barry et al. in Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa; Zacchaeus Anywaine et al. in Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial).
Rare Serotypes and Alternative Capsids
Instead of relying on common human viral strains like HAdV-C5, researchers are shifting toward rare viral serotypes or non-human viral backbones that have low global seroprevalence.
As explored by JD Fuchs et al. in DNA and recombinant adenovirus serotype 35 and 5 preventive HIV-1 vaccines with Env A inserts elicit cross-clade binding and V1V2 antibodies, utilizing rare serotypes like adenovirus serotype 35 (rAd35) allows the therapeutic payload to bypass the widespread pre-existing immunity found in the general population. Similarly, researchers have investigated alternative delivery platforms, such as recombinant rabies virus vectors (Hongli Jin et al. in An inactivated recombinant rabies virus displaying the Zika virus prM-E induces protective immunity against both pathogens) or bacteriophage platforms (Mengling Li et al. in Bacteriophage T4 Vaccine Platform for Next-Generation Influenza Vaccine Development), to ensure the delivery vehicle remains unrecognized by human memory B cells.
Capsid Shielding and Localized Expression
When alternative serotypes are unavailable, structural modification of the viral envelope or capsid can shield the virus from antibody recognition. Huaiping Shi in Inhibitory effects of human lactoferrin on U14 cervical carcinoma through upregulation of the immune response highlights the necessity of developing modified viral envelopes or non-viral vectors to sustain therapeutic efficacy against pre-existing immunity.
However, engineering these shields requires a delicate balance. The vector must remain "biologically quiet" to avoid triggering non-specific mucosal or systemic immune activation that could inadvertently clear the therapy or endanger the patient (Catia Perciani et al. in Live attenuated varicella-zoster virus vaccine does not induce HIV target cell activation). By combining capsid engineering with localized delivery or dual-gene modifications that reshape the microenvironment, modern viral therapeutics aim to maximize payload expression before the host's immune system can mount a neutralizing response (Haoran Zhu et al. in Engineered oncolytic virus expressing B7H3-targeting BiTE enhances antitumor T-cell immune response; Yuan Meng et al. in RCAd-LTH-shPD-L1, a double-gene recombinant oncolytic adenovirus with enhanced antitumor immunity, increases lymphocyte infiltration and reshapes the tumor microenvironment).
Key Foundational Work
Immunization with Adenoviral Vectors Carrying Recombinant IL-12 and E7 Enhanced the Antitumor Immunity against Human Papillomavirus 16-associated Tumor (2005) — contributed 1 concept elements to this direction.
P19-08. Immunisation with recombinant HLA class I and II, HIV-1gp140 and SIVp27 antigens elicits protection against SHIV-SF162P4 infection in rhesus macaques (2009) — contributed 1 concept elements to this direction.